VNDA Vanda Pharmaceuticals Inc.

14.99
-0.12  -1%
Previous Close 15.11
Open 15.11
Price To Book 1.99
Market Cap 799,522,904
Shares 53,337,085
Volume 675,982
Short Ratio
Av. Daily Volume 577,287
Stock charts supplied by TradingView

NewsSee all news

  1. Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®

    WASHINGTON, Jan. 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced today that the U.S. Supreme Court has denied the petition for a writ of certiorari filed by West-Ward Pharmaceuticals

  2. Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award

    WASHINGTON, Dec. 12, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will

  3. Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences

    WASHINGTON, Nov. 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it will participate at the following upcoming investor conferences in November 2019: The Stifel 2019

  4. Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results

    WASHINGTON, Nov. 6, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019. "These results affirm

  5. Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019

    WASHINGTON, Oct. 30, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2019 and provide a general business overview, on Wednesday,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial initiated 2Q 2019.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
CRL issued August 19, 2019.
HETLIOZ (tasimelteon)
Jet Lag Disorder
sNDA filing due 4Q 2019. Moved to 1Q 2020 due to no update.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 data due 1Q 2020.
Tradipitant - EPIONE 1
Atopic dermatitis
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies
Phase 3 trial to be initiated 4Q 2019.
Tradipitant
Motion sickness
Phase 3 trial to commence 4Q 2019.
Fanapt
Bipolar Disorder
Phase 3 trial to be initiated by YE 2019.
HETLIOZ (tasimelteon)
Delayed sleep phase disorder (DSPD)
Phase 3 enrolment commenced October 2019.
Tradipitant - EPIONE 2
Atopic dermatitis

Latest News

  1. Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt®

    WASHINGTON, Jan. 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced today that the U.S. Supreme Court has denied the petition for a writ of certiorari filed by West-Ward Pharmaceuticals

  2. Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award

    WASHINGTON, Dec. 12, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will

  3. Vanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences

    WASHINGTON, Nov. 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that it will participate at the following upcoming investor conferences in November 2019: The Stifel 2019

  4. Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results

    WASHINGTON, Nov. 6, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019. "These results affirm

  5. Vanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019

    WASHINGTON, Oct. 30, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the third quarter 2019 and provide a general business overview, on Wednesday,

  6. Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors

    WASHINGTON, Oct. 28, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Anne Sempowski Ward has joined the company's Board of Directors, effective October 28, 2019. Following

  7. Vanda Pharmaceuticals Applauds the EPA's Landmark Commitment to Eliminate Animal Testing and Urges the Food and Drug Administration to End Unnecessary and Scientifically Flawed Animal Toxicity Studies

    WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high